Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor

Related Experiment Video

Updated: Jul 17, 2026

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

Andriani Athanasiou1, Paul A Smith, Sara Vakilpour

  • 1School of Biomedical Sciences, University of Nottingham, Nottingham NG7 2UH, UK.

Biochemical and Biophysical Research Communications
|January 12, 2007
PubMed

Insights

Transient Receptor Potential V1 (TRPV1) channel ligands, including agonists and antagonists, induced cancer cell death. These TRPV1 compounds also inhibited mitochondrial function, suggesting potential as novel anti-cancer agents.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • The Transient Receptor Potential Vanilloid 1 (TRPV1) channel is implicated in various physiological processes.
  • TRPV1 ligands are known to interact with cellular signaling pathways.
  • Understanding the non-canonical effects of TRPV1 ligands is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the effects of TRPV1 channel agonists and antagonists on cancer cell morphology.
  • To determine the impact of these TRPV1 ligands on mitochondrial function.
  • To explore the potential of TRPV1 ligands as anti-cancer agents.

Main Methods:

  • Time-lapse photomicroscopy of H460 lung cancer cells.
  • Immunoblot analysis for TRPV1 channel expression.
  • Measurement of oxygen consumption and mitochondrial membrane potential in isolated rat heart mitochondria.
  • Assessment of mitochondrial hydrogen peroxide production.

Main Results:

  • TRPV1 agonists (E)-capsaicin and resiniferatoxin, and antagonists capsazepine and SB366791, induced morphological changes indicative of apoptosis/necrosis in H460 cells.
  • TRPV1 channel immunoreactivity was detected in rat brain but not in H460 cells or rat heart mitochondria.
  • All four ligands inhibited mitochondrial respiration and membrane potential in a concentration-dependent manner.
  • (E)-Capsaicin and capsazepine modulated mitochondrial hydrogen peroxide production.

Conclusions:

  • TRPV1 ligands act as mitochondrial inhibitors, inducing apoptosis and/or necrosis through non-receptor-mediated mechanisms.
  • These findings support the investigation of TRPV1 ligands as potential anti-cancer therapeutics.
  • TRPV1 ligands may offer a novel strategy for cancer treatment by targeting mitochondrial dysfunction.

More Related Videos

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 109:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...